L2 Asset Management LLC Buys Shares of 10,049 IQVIA Holdings Inc. $IQV

L2 Asset Management LLC purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the 2nd quarter, Holdings Channel reports. The firm purchased 10,049 shares of the medical research company’s stock, valued at approximately $1,942,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Vega Investment Solutions acquired a new stake in IQVIA in the 2nd quarter valued at approximately $709,000. SaddleRock Capital Management LLC acquired a new position in IQVIA during the 2nd quarter worth $9,551,000. Ally Financial Inc. acquired a new position in IQVIA during the 2nd quarter worth $1,063,000. Cibc World Market Inc. bought a new position in shares of IQVIA in the second quarter worth $11,294,000. Finally, Castlefield Investment Partners LLP acquired a new position in shares of IQVIA during the second quarter valued at $601,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently weighed in on IQV. Robert W. Baird upped their price objective on shares of IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Weiss Ratings raised shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Royal Bank Of Canada boosted their price target on shares of IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on shares of IQVIA in a report on Thursday, July 9th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $200.00 target price (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus price target of $241.88.

Insiders Place Their Bets

In related news, insider Keriann Cherofsky sold 558 shares of the company’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the transaction, the insider directly owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. The trade was a 15.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric Sherbet sold 5,000 shares of the stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total value of $1,245,800.00. Following the completion of the sale, the insider directly owned 20,999 shares of the company’s stock, valued at approximately $5,232,110.84. This represents a 19.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 12,913 shares of company stock worth $3,098,793 over the last three months. Company insiders own 1.70% of the company’s stock.

IQVIA Stock Performance

Shares of IQV opened at $260.30 on Tuesday. The company has a 50-day moving average of $214.97 and a two-hundred day moving average of $187.62. The stock has a market cap of $42.85 billion, a price-to-earnings ratio of 32.30, a PEG ratio of 2.21 and a beta of 1.18. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $261.88.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. During the same quarter in the prior year, the firm earned $2.81 EPS. The firm’s quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities research analysts expect that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA announced that its Board of Directors has initiated a stock buyback plan on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board of directors believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.